Kennedy Capital Management LLC Makes New Investment in Capricor Therapeutics Inc (NASDAQ:CAPR)

Kennedy Capital Management LLC bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 144,250 shares of the biotechnology company's stock, valued at approximately $1,991,000. Kennedy Capital Management LLC owned approximately 0.32% of Capricor Therapeutics as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock valued at $1,536,000 after acquiring an additional 37,868 shares in the last quarter. Magnus Financial Group LLC purchased a new position in Capricor Therapeutics during the 4th quarter valued at about $276,000. State Street Corp raised its holdings in shares of Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock valued at $7,792,000 after purchasing an additional 111,291 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Capricor Therapeutics by 419.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after purchasing an additional 45,381 shares during the period. Finally, Swiss National Bank bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $930,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CAPR shares. HC Wainwright reissued a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $34.50.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR traded up $1.61 during mid-day trading on Friday, hitting $11.25. 1,508,377 shares of the company's stock traded hands, compared to its average volume of 1,475,780. The company has a fifty day moving average of $12.33 and a 200 day moving average of $15.03. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40. The company has a market capitalization of $513.87 million, a P/E ratio of -10.61 and a beta of 4.65.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15. The firm had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. On average, research analysts expect that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.